Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Combining radiotherapy and immunotherapy in head and neck cancer

Markus Hecht, MD, PhD, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany, outlines the rationale of combining immunotherapy and radiotherapy in patients with head and neck cancer. Radiotherapy results in changes in the tumor microenvironment that may lead to an improved response to immune checkpoint blockade. Dr Hecht also touches on the importance of targeting novel checkpoint blockades in the future to optimize treatment approaches. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

Disclosures

Markus Hecht, MD, PhD, has received an advisory role, speakers’ bureau, honoraria, travel expenses, and research funding from Merck Serono, MSD and BMS, research funding from AstraZeneca and Novartis, as well as travel expenses from Teva.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.